Integrated BioPharma Reports Results for its Quarter Ended December 31, 2024
Integrated BioPharma (OTCQX:INBP) reported financial results for Q4 2024, showing improved performance. Revenue increased by 9.6% to $12.6 million compared to $11.5 million in Q4 2023. The company turned around from an operating loss of $0.5 million in Q4 2023 to an operating income of $0.2 million in Q4 2024.
For the six-month period ended December 31, 2024, revenue grew 7.4% to $26.2 million, with operating income of $0.7 million compared to a loss of $0.5 million in the same period of 2023. Net income per share improved to $0.01 from a loss of $(0.02) in the comparable period. The company's two largest customers in the Contract Manufacturing Segment accounted for 82% of total revenue, down from 90% in the previous year, indicating successful customer base expansion.
Integrated BioPharma (OTCQX:INBP) ha riportato i risultati finanziari per il quarto trimestre del 2024, mostrando un miglioramento delle performance. I ricavi sono aumentati del 9,6% a 12,6 milioni di dollari rispetto a 11,5 milioni di dollari nel quarto trimestre del 2023. L'azienda ha invertito una perdita operativa di 0,5 milioni di dollari nel quarto trimestre del 2023, ottenendo un reddito operativo di 0,2 milioni di dollari nel quarto trimestre del 2024.
Per il periodo di sei mesi terminato il 31 dicembre 2024, i ricavi sono cresciuti del 7,4% a 26,2 milioni di dollari, con un reddito operativo di 0,7 milioni di dollari rispetto a una perdita di 0,5 milioni di dollari nello stesso periodo del 2023. L'utile netto per azione è migliorato a 0,01 dollari rispetto a una perdita di 0,02 dollari nel periodo comparabile. I due maggiori clienti dell'azienda nel Segmento di Produzione a Contratto hanno rappresentato l'82% dei ricavi totali, in calo rispetto al 90% dell'anno precedente, indicando un'espansione riuscita della base clienti.
Integrated BioPharma (OTCQX:INBP) informó resultados financieros para el cuarto trimestre de 2024, mostrando un mejor rendimiento. Los ingresos aumentaron un 9.6% a 12.6 millones de dólares en comparación con 11.5 millones de dólares en el cuarto trimestre de 2023. La compañía pasó de una pérdida operativa de 0.5 millones de dólares en el cuarto trimestre de 2023 a un ingreso operativo de 0.2 millones de dólares en el cuarto trimestre de 2024.
Para el período de seis meses que finalizó el 31 de diciembre de 2024, los ingresos crecieron un 7.4% a 26.2 millones de dólares, con un ingreso operativo de 0.7 millones de dólares en comparación con una pérdida de 0.5 millones de dólares en el mismo período de 2023. El ingreso neto por acción mejoró a 0.01 dólares desde una pérdida de 0.02 dólares en el período comparable. Los dos mayores clientes de la compañía en el Segmento de Fabricación por Contrato representaron el 82% de los ingresos totales, en comparación con el 90% del año anterior, lo que indica una exitosa expansión de la base de clientes.
Integrated BioPharma (OTCQX:INBP)는 2024년 4분기 재무 결과를 발표하며 성과 개선을 보여주었습니다. 수익은 9.6% 증가하여 1260만 달러를 기록했으며, 이는 2023년 4분기의 1150만 달러와 비교됩니다. 회사는 2023년 4분기의 50만 달러 운영 손실에서 2024년 4분기의 20만 달러 운영 수익으로 반전했습니다.
2024년 12월 31일 종료된 6개월 기간 동안 수익은 7.4% 증가하여 2620만 달러에 달했으며, 운영 수익은 70만 달러로 2023년 같은 기간의 50만 달러 손실과 비교됩니다. 주당 순이익은 0.01달러로 개선되었고, 이는 비교 기간의 0.02달러 손실에서 나아진 것입니다. 계약 제조 부문에서 회사의 두 주요 고객은 전체 수익의 82%를 차지했으며, 이는 작년의 90%에서 감소한 수치로, 고객 기반 확장의 성공을 나타냅니다.
Integrated BioPharma (OTCQX:INBP) a annoncé des résultats financiers pour le quatrième trimestre de 2024, montrant une amélioration des performances. Le chiffre d'affaires a augmenté de 9,6 % pour atteindre 12,6 millions de dollars contre 11,5 millions de dollars au quatrième trimestre de 2023. L'entreprise est passée d'une perte opérationnelle de 0,5 million de dollars au quatrième trimestre de 2023 à un revenu opérationnel de 0,2 million de dollars au quatrième trimestre de 2024.
Pour la période de six mois se terminant le 31 décembre 2024, le chiffre d'affaires a augmenté de 7,4 % pour atteindre 26,2 millions de dollars, avec un revenu opérationnel de 0,7 million de dollars par rapport à une perte de 0,5 million de dollars au cours de la même période en 2023. Le bénéfice net par action s'est amélioré à 0,01 dollar contre une perte de 0,02 dollar au cours de la période comparable. Les deux plus grands clients de l'entreprise dans le secteur de la fabrication sous contrat ont représenté 82 % du chiffre d'affaires total, contre 90 % l'année précédente, indiquant une expansion réussie de la base de clients.
Integrated BioPharma (OTCQX:INBP) hat die finanziellen Ergebnisse für das 4. Quartal 2024 bekannt gegeben, die eine Verbesserung der Leistung zeigen. Der Umsatz stieg um 9,6 % auf 12,6 Millionen Dollar im Vergleich zu 11,5 Millionen Dollar im 4. Quartal 2023. Das Unternehmen hat sich von einem operativen Verlust von 0,5 Millionen Dollar im 4. Quartal 2023 zu einem operativen Einkommen von 0,2 Millionen Dollar im 4. Quartal 2024 gewandelt.
Für den sechsmonatigen Zeitraum bis zum 31. Dezember 2024 wuchs der Umsatz um 7,4 % auf 26,2 Millionen Dollar, mit einem operativen Einkommen von 0,7 Millionen Dollar im Vergleich zu einem Verlust von 0,5 Millionen Dollar im gleichen Zeitraum 2023. Der Nettogewinn pro Aktie verbesserte sich auf 0,01 Dollar von einem Verlust von 0,02 Dollar im vergleichbaren Zeitraum. Die beiden größten Kunden des Unternehmens im Bereich Vertragsfertigung machten 82 % des Gesamtumsatzes aus, im Vergleich zu 90 % im Vorjahr, was auf eine erfolgreiche Erweiterung der Kundenbasis hinweist.
- Revenue increased 9.6% YoY to $12.6 million in Q4 2024
- Turned operating loss into $0.2 million operating profit in Q4 2024
- Six-month revenue grew 7.4% to $26.2 million
- Customer concentration reduced from 90% to 82%, showing successful diversification
- Achieved net income of $0.4 million for six months vs previous loss of $0.4 million
- High customer concentration with 82% of revenue from two customers
- Minimal earnings per share at $0.01 for six months
HILLSIDE, NJ / ACCESS Newswire / February 13, 2025 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2024.
Revenue for the quarter ended December 31, 2024 was
Revenue for the six-month period ended December 31, 2024 was
For the quarters ended December 31, 2024 and 2023, the Company had net income of
For the six-month periods ended December 31, 2024 and 2023, the Company had net income of
"Our revenues increased by
A summary of our financial results for the three months and six months ended December 31, 2024 and 2023 follows:
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(Unaudited)
|
| Three Months Ended |
|
| Six Months Ended |
| ||||||||||
|
| December 31, |
|
| December 31, |
| ||||||||||
| 2024 |
|
| 2023 |
|
| 2024 |
|
| 2023 |
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total revenue |
| $ | 12,614 |
|
| $ | 11,509 |
|
| $ | 26,231 |
|
| $ | 24,424 |
|
Cost of sales |
|
| 11,443 |
|
|
| 10,989 |
|
|
| 23,689 |
|
|
| 23,072 |
|
Gross profit |
|
| 1,171 |
|
|
| 520 |
|
|
| 2,542 |
|
|
| 1,352 |
|
Selling and administrative expenses |
|
| 969 |
|
|
| 972 |
|
|
| 1,850 |
|
|
| 1,858 |
|
Operating income (loss) |
|
| 202 |
|
|
| (452 | ) |
|
| 692 |
|
|
| (506 | ) |
Other income (expense), net |
|
| (17 | ) |
|
| - |
|
|
| (3 | ) |
|
| 8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Income (loss) before income taxes |
|
| 185 |
|
|
| (452 | ) |
|
| 689 |
|
|
| (498 | ) |
Income tax expense (benefit), net |
|
| 69 |
|
|
| (70 | ) |
|
| 314 |
|
|
| (57 | ) |
Net income (loss) |
| $ | 116 |
|
| $ | (382 | ) |
| $ | 375 |
|
| $ | (441 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
| $ | 0.00 |
|
| $ | (0.01 | ) |
| $ | 0.01 |
|
| $ | (0.02 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted |
| $ | 0.00 |
|
| $ | (0.01 | ) |
| $ | 0.01 |
|
| $ | (0.02 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
| 30,174,664 |
|
|
| 30,099,610 |
|
|
| 30,137,137 |
|
|
| 30,032,762 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted |
|
| 31,303,011 |
|
|
| 30,099,610 |
|
|
| 30,810,401 |
|
|
| 30,032,762 |
|
About Integrated BioPharma Inc. (INBP)
Integrated BioPharma, Inc. ("INBP") is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words "expects," "anticipates," believes," intends," "estimates," "should," "would," "strategy," "plan" and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and the tightened labor markets; the impact of the war in Ukraine; the impact of the Israel-Hamas war; our ability to expand our customer base and other risks and uncertainties described in the section entitled "Risk Factors" in INBP's most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.
Contact:
Dina Masi, CFO
Integrated BioPharma, Inc.
investors@ibiopharma.com
888.319.6962
SOURCE: Integrated BioPharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What was INBP's revenue growth in Q4 2024?
How much did INBP earn per share in the six months ended December 31, 2024?
What percentage of INBP's revenue came from its top two customers in 2024?
How did INBP's operating income change in Q4 2024 compared to Q4 2023?
What was INBP's total revenue for the six months ended December 31, 2024?
